Social Workers' Attitudes and Beliefs about MDMA-Assisted Therapy for Adolescents with PTSD.
Maha N. Mian, Jordan Horan, Taweh Hunter, Alan K. Davis, Stacey B. Armstrong
Social Work April 1, 2025 DOI: 10.1093/sw/swaf005 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 222 |
| Population | Social workers |
| Interventions | MDMA-assisted therapy selective serotonin reuptake inhibitor-assisted therapy |
| Topics | MDMA PTSD |
| Keywords | Adolescents Psychedelics Mental health treatment Psychedelic Therapy MDMA Adolescent psychiatry teens Youth Young adults Trauma Ssris selective |
| Citations | 1 |
| Key findings | Social workers rated SSRI-assisted therapy as significantly more acceptable, appropriate, and feasible than MDMA-assisted therapy for treating adolescent treatment-resistant PTSD. |
Abstract
Given the widespread interest and ongoing study on MDMA-assisted therapy (MDMA-AT) for PTSD, its implications for unique populations-such as adolescents-require further understanding. Social workers will likely play a crucial role in the potential implementation of this intervention, but their perspectives remain unknown. The study includes 222 social workers randomized to read one of two vignettes about MDMA-AT or selective serotonin reuptake inhibitor-assisted therapy (SSRI-AT) for treating adolescent treatment-resistant PTSD. Participants rated each treatment's acceptability, appropriateness, and feasibility, followed by drug stigma, perceptions of drug risk, and psychedelic knowledge. Participants in the SSRI-AT condition reported significantly higher mean ratings of treatment acceptability (p < .001; d = .72), appropriateness (p < .001; d = .72), and feasibility (p < .001; d =. 64). In the MDMA-AT condition, perceptions of MDMA risk were greater (p < .001; d = .59) and psychedelic stigma positively correlated with perceived risk of MDMA (r = .46, p < .001). Moreover, greater psychedelic knowledge was significantly related to less stigma (r = -.33, p < .001) and less perceived risk of MDMA (r = -.21, p < .001). Concerns among social workers about the acceptability, appropriateness, and feasibility of MDMA-AT for adolescents with PTSD may limit clinical trial recruitment, engagement, and future implementation.
Comparable studies
Other randomized controlled trials on MDMA for PTSD, most cited first.
Citations in the library
Cites 10
- MDMA‐Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta‐Analysis The Journal of Clinical Pharmacology October 28, 2021
- Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States Journal of Psychoactive Drugs September 1, 2021
- MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. FOCUS: The Journal of Lifelong Learning in Psychiatry July 1, 2023
- Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey Journal of Psychoactive Drugs August 19, 2021
- A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis Journal of Psychopharmacology December 20, 2020
and 5 more in the library